Dr Timothy Yap speaks to ecancer about KEYLYNK-007: a tumour-agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency-positive advanced cancers.

The KEYLYNK-007 trial investigates the combination of olaparib and pembrolizumab for advanced cancers, focusing on patients with specific genetic mutations.

It categorises patients into three subgroups based on biomarker status, including those with BRCA mutations and HRD-positive tumours.

The trial shows promising results, especially in BRCA mutation cancers, with a median response duration of 19.1 months, and ongoing analysis for additional indications.